Recherches "plusieurs pathologies" CHECK'UP Prospective Cohort Study to Identify the Predictive Factors of Response to PD-1 or PD-L1 Antagonists. Paris
Mélanome uvéal et tumeurs oculaires IMCgp100-202 A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma Paris
Appareil Digestif SCARCE (C17-02 PRODIGE 60) A Non-comparative Randomized 2:1 Phase II Study of Docetaxel, Cisplatin, and 5-fluorouracil in Combination or Not With Atezolizumab in Patients With Metastatic or Unresectable Locally Advanced Squamous Cell Anal Carcinoma Paris
Sein Néoadjuvant ALIENOR Detection of Circulating Tumoral DNA Mutations (Sequential Assessment) Following Neoadjuvant Chemotherapy for Breast Cancer: Clinical Validity (ALIENOR Study) Paris, Saint-Cloud
Recherches "plusieurs pathologies" NIPINEC (GCO-001) A GCO Trial Exploring the Efficacy and Safety of Nivolumab Monotherapy or Nivolumab Plus Ipilimumab in Pre-treated Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) Paris NICOLAS GIRARD
Sein métastatique RH+ XENERA-1 (BI 1280-0022) A multi-centre, double-blind, placebo-controlled,randomised phase II trial to compare efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in post-menopausal women with HR+ / HER2- metastatic breast cancer and non-visceral disease Paris
Recherches "plusieurs pathologies" CA209-848 A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination With Ipilimumab or Nivolumab Monotherapy in Participants With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) Paris EMANUELA ROMANO
Recherches "plusieurs pathologies" ARIANES A multicenter, open label, phase II basket trial exploring the efficacy and safety of the combination of rucaparib (PARP inhibitor) and atezolizumab (anti-PD-L1 antibody) in patients with DNA repair-deficient or platinum-sensitive solid tumors Paris
VADS CA209-9T9 ProNiHN A FRENCH, PROSPECTIVE, NON-INTERVENTIONAL RESEARCH (NIR) OF NIVOLUMAB IN PATIENTS WITH SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) PROGRESSING ON OR AFTER PLATINUM-BASED THERAPY Paris CHRISTOPHE LE TOURNEAU
Recherches "plusieurs pathologies" MS1000070-176 An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants From Multiple Avelumab (MSB0010718C) Clinical Studies Paris